Compare CETY & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | CLDI |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 8.0M |
| IPO Year | N/A | N/A |
| Metric | CETY | CLDI |
|---|---|---|
| Price | $0.55 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 209.1K | 80.3K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,282,095.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.96 |
| 52 Week High | $11.20 | $19.20 |
| Indicator | CETY | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 30.37 |
| Support Level | $0.70 | $0.97 |
| Resistance Level | $0.84 | $1.12 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 3.92 | 17.11 |
Clean Energy Technologies Inc is clean energy and environmentally sustainable technologies company offering heat recovery solutions products. In addition, it also provides engineering and manufacturing solutions focused on other energy-efficient and environmentally sustainable technologies. The company's principal product is the Clean Cycle generator, offered by Heat Recovery Solutions. The company's engineering and manufacturing resources support its heat recovery solutions business. It has four segments: Clean Energy HRS & CETY Europe, CETY Renewables Waste to Energy Solutions, Engineering and Manufacturing Business and CETY HK. It serves various markets, including industrial, aerospace, military, instrumentation, and medical.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.